Trial intelligence / Profile preview

Continuous bevacizumab beyond progression in elderly metastatic colorectal cancer

2014-003844-11Phase 4Terminated

Sponsor
University Hospital, Linköping
Start
Dec 2014
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of bevacizumab in metastatic colorectal adenocarcinoma (mCRC), sponsored by University Hospital, Linköping. Primary endpoint: Overall survival. Started Dec 2014; status: terminated.

02

Drugs

bevacizumab
03

Conditions

metastatic colorectal adenocarcinoma (mCRC)

Beyond the preview

Go deeper on 2014-003844-11.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2014-003844-11.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call